Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | ANPEP | P15144 | 4/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.47 |
| ▸ | ACP3 | P15309 | 4/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14818493 | 0.83 | SRC (0.48) | SRCDPP4ANPEPLAP3ACP3 | |
| SCHEMBL11286460 | 0.80 | SRC (0.54) | SRCANPEPLAP3ACP3ERAP1 | |
| SCHEMBL875769 | 0.77 | SRC (0.60) | SRCANPEPLAP3ACP3 | |
| SCHEMBL14818500 | 0.76 | LAP3 (0.65) | ANPEPLAP3ACP3ERAP1ERAP2 | |
| SCHEMBL14831728 | 0.74 | SRC (0.52) | SRCDPP4ANPEPLAP3ACP3 | |
| SCHEMBL11061163 | 0.74 | SRC (0.56) | SRCACP3 | |
| SCHEMBL4454292 | 0.74 | ACP3 (0.66) | SRCACP3 | |
| SCHEMBL8729175 | 0.73 | SRC (0.50) | SRCDPP4ANPEPLAP3ACP3 | |
| SCHEMBL8729170 | 0.73 | SRC (0.50) | SRCDPP4ANPEPLAP3ACP3 | |
| SCHEMBL499206 | 0.73 | SRC (0.46) | SRCANPEPLAP3ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9492466-B2 | Beta-hydroxy-gamma-aminophosphonates for treating immune disorders | NUCITEC S.A. DE C.V. (MX) | 2016-11-15 | — | — | US | disclosed |
| US-20140107079-A1 | Beta-hydroxy-gamma-aminophosphonates for Treating Immune Disorders | Nucites S.A. de C.V. (MX) | 2014-04-17 | — | — | US | disclosed |
| US-8536362-B2 | β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof | NUCITEC S.A. DE C.V. (MX) | 2013-09-17 | — | — | US | disclosed |
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | NUCITEC S.A. DE C.V. (MX) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107079-A1 | Beta-hydroxy-gamma-aminophosphonates for Treating Immune Disorders | IFNG, HPGDS, AASDHPPT | SRC 2945/4885DPP4 2000/4885ANPEP 295/4885 |
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | CPT1A, ACAT1, ABAT | SRC 4175/4885DPP4 539/4885ANPEP 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.